Because I do not trust LP and the financials are a hot mess.
There is no point to rehashing reasons for this opinion, but it does answer your question.
W/o these, I would consider the company a typical risky biotech. The trial issues might well be outweighed by the low market cap.
One thing I have learned in this field is not to fall in love with the theory of some drug/agent MOA. They all tend to sound nice on paper. They all have backing by solid experts. And most fail in the clinic.
On your other question:
... why the FDA would have lifted the hold a couple weeks ago if they failed PFS.
The FDA tells NWBO they can not enroll patients into the trial because of X.
NWBO discusses for a year
NWBO sends a CR saying they will no longer enroll in the trial.
Of course the FDA would accept that response, as it is exactly what they asked for, no more enrolled.
I do not claim to know what X is. I think that futility is possible. So is manufacturing. I think safety is unlikely. And then the unknowns. .
News 
Market Data 
Discover 
